Oncolytics Biotech and Johnson & Johnson operate within the larger oncology ecosystem, with J&J setting market standards through successful acquisitions.
4 reports, 4 independent
Updated May 26
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 4
- Developments
- 5
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oncolytics Biotech and Johnson & Johnson operate within the larger oncology ecosystem, with J&J setting market standards through successful acquisitions.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Johnson & Johnson acquired AbioMed in 2022, and the FDA subsequently issued an early alert regarding device failure related to the acquisition.Sub-event
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Sub-event
- Johnson & Johnson faces product-related developments, including exclusive distribution for NOVOSIS bone graft and jury verdicts tied to talc litigation risk.Sub-event
Both companies operate in the oncology ecosystem, with J&J noted for setting market standards via acquisitions.1 source
J&J clinical data supports new treatment strategies.1 source
Keep exploring
The entities involved
-
Oncolytics Biotech
Nothing else this week.
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
Related events
- Johnson & Johnson highlighted growth opportunities within the MedTech sector.
- MedTech is identified as a soft spot in J&J case.
- Medical device sales are up in the U.S., but major players like J&J are facing market headwinds due to the VBP program in China.
- JNJ secured marketing authorization from the U.S. FDA, and its Ottava platform challenges ISRG's market dominance.
- Johnson & Johnson and Recordati Industria Chimica E Farmaceutica are noted as large-cap healthcare companies.
Coverage
Newest first; wire copies grouped- clevelandstar.com
- theusnews.com
- hawaiitelegraph.com
- GlobeNewswireRYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer New data demonstrate amivantamab c